Digitek digoxin is a prescription drug widely used for individuals suffering from heart conditions such as congestive heart failure or irregular heart rhythms. However, a recent manufacturer's error caused the drug to be released with double the dose prescribed, potentially causing toxicity among patients.
Digitek digoxin is a prescription drug that treats heart conditions such as congestive heart failure or irregular heart rhythms. The drug, also known as digitalis, lanoxin or Lanoxicaps, is derived from a plant extract.
It is widely used in the treatment of various heart conditions, namely atrial fibrilation and atrial flutter, both abnormal heart rhythms It is sometimes prescribed for heart failure that cannot be controlled by other medication.
Digoxin is commonly marketed under the name Lanoxin, Digitek, and Lanoxicaps, and has been manufactured widely in the United States by the pharmaceutical company Actavis Totowa LLC, formerly known as formerly known as Amide Pharmaceutical, Inc.
It is the New Jersey headquartered and United States based manufacturing division of the international pharmaceutical company Actavis Group, a well known manufacturer and distributor of generic versions of previously name-brand drugs. Digitek Recall
On April 25, 2008, Actavis Totowa initiated a Class 1 nationwide recall of Digitek (digoxin tablets, USP, all strengths) for oral use. These are made available for distribution through Mylan Pharmaceuticals, Inc. under a "Bertek" labeling, by UDL Laboratories Inc. under a "UDL" label. Also, the Activis Web site claims that:
The voluntary all-lot recall is due to the possibility that tablets with double the appropriate thickness may have been commercially released. These tablets may contain twice the approved level of active ingredient than is appropriate.
Digitek Side Effects
The posting indicates, as do other reports, that both of the Mylan Pharmaceuticals laboratories(Bertek and UDL) incorrectly manufactured the Digitek pills with double the amount of active medicine, spiking the risk of side effects dramatically.
Common side effects include: loss of appetite, nausea, vomiting, diarrhea, blurred vision, visual disturbances (yellow-green halos), confusion, drowsiness, dizziness, nightmares, agitation, and/or depression. Less frequent adverse effects include: acute psychosis, delirium, amnesia, and the possibility of life-threatening heart complications, including additional arrythmia episodes and heart failure. It may be possible for Digitek digoxin to cause deadly overdoses.
Digitek Lawsuits
Indeed, several postings on consumer health and recall websites reflect the outrage over this egregious error. Reports of illnesses, complications and even deaths consistent with the relevant side effects of overdosing have been surfacing in the press over the last month.
It may be possible, because of the digoxin recall that individuals affected may be able to be involved in a Digitek digoxin class action lawsuit.
In fact, several law firms have already reported the beginnings of proceedings in such cases where overdoses from Digoxin have injured clients and caused dangerous, damaging, or deadly side effects.
Medical Journal Finds NSAIDs Offer More Harm Than Good to Heart Failure Patients
Recently, a medical journal discovered more harmful side effects among patients consuming nonsteroidal anti-inflammatory drugs (NSAIDs) than helpful side effects among heart failure patients.Peanut Butter Recall Sickens Hundreds, Criminal Investigation Underway
The recent peanut butter recall has resulted in nearly 600 illnesses and at least eight fatalities, prompting a criminal investigation by government officials. Despite ongoing recalls, the contaminated peanut butter continues to pose a significant health risk to many Americans.Researchers Study Toxicity Levels of Mesothelioma Treatments
Researchers are attempting to increase the validity of mesothelioma treatments among patients suffering from the fatal condition by testing the highest dosage levels that can be administered to patients without resulting in toxicity levels among individuals.